5 results
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
#Candidiasis #candida ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Bartonella Infections in HIV-AIDS
Preferred Therapy
For Bacillary Angiomatosis, Peliosis Hepatis, Bacteremia, and Osteomyelitis:
#Bartonella #Bartonellosis ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Treponema pallidum Infections (Syphilis) to Prevent Disease in HIV-AIDS
Early Stage (Primary, Secondary,
1 dose (BII) Late-Latent ... 28 days (BIII) Late-Stage ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Histoplasma Capsulatum Infections in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
a hyperendemic rate ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
Therapy—For Immediate Sight ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology